Welcome to our dedicated page for AUTOLUS THERAPEUTICS PLC SEC filings (Ticker: AUTL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Autolus Therapeutics plc filings document a foreign-issuer ADS structure and material events for a commercial-stage T cell therapy company. The company’s American Depositary Shares trade on the Nasdaq Global Select Market, with each ADS representing one ordinary share, while the ordinary shares are registered in connection with the ADS listing.
Recent Form 8-K disclosures cover financial results, corporate presentations, AUCATZYL revenue updates, pipeline and manufacturing matters, and a master service agreement for lentiviral vector supply used in CAR-T products. The filings also record operational efficiency costs, changes in the company’s independent registered public accounting firm, internal-control disclosures, executive and compensation matters, governance actions and Regulation FD materials.
Autolus Therapeutics plc is registering 16,645,656 ordinary shares represented by American Depositary Shares (ADSs) on Form S-8 for its equity compensation programs. This includes 3,000,000 ADSs for the 2025 Employee Share Purchase Plan, 3,000,000 ADSs for the 2025 Inducement Plan, and 10,645,656 ADSs for additional awards under the 2018 Equity Incentive Plan following an automatic increase effective October 1, 2025. These ADSs will be used for employee and new-hire equity grants under the company’s existing plans, supplementing amounts previously registered on earlier S-8 filings.
Autolus Therapeutics plc filed Prospectus Supplement No. 4 covering the resale of up to 54,584,250 ADSs by selling securityholders. This includes 51,318,944 ADSs representing ordinary shares and up to 3,265,306 ADSs issuable upon exercise of outstanding warrants. The ADSs trade on Nasdaq as AUTL; the closing price was $1.50 on November 11, 2025.
The supplement attaches the company’s Q3 2025 report. For the quarter, Autolus recorded $21.1 million in product revenue and a net loss of $79.1 million. As of September 30, 2025, cash and cash equivalents were $86.1 million and marketable securities were $281.3 million. 266,143,286 ordinary shares were outstanding as of November 11, 2025.
Autolus Therapeutics plc filed an 8-K announcing it furnished its financial results for the quarter ended September 30, 2025 and provided a corporate update. The results were furnished as Exhibit 99.1, and an updated corporate presentation was furnished as Exhibit 99.2; these materials are furnished, not filed.
The Board noted that Chief Financial Officer Rob Dolski resigned as principal accounting officer but remains CFO and Principal Financial Officer. Patrick McIlvenny was appointed Principal Accounting Officer effective November 7, 2025, with no additional compensation and no related-party or family relationships disclosed.
Wellington Management filed an amended Schedule 13G reporting its position in Autolus Therapeutics plc (AUTL) common stock. The filing lists three related Wellington entities organized in MASSACHUSETTS and DELAWARE that collectively report 0.0% beneficial ownership of the class and 0 shares of sole voting or dispositive power. The securities are owned of record by clients of Wellington investment advisers and are held in the ordinary course of business, with no client reported as having more than 5% of the class. The cover lists the issuer address in London and the event date 09/30/2025; the filing is signed on 10/07/2025 by a Wellington regulatory analyst.
Autolus Therapeutics plc reported the first commercial product revenue following U.S. launch of AUCATZYL: $20.9 million in Q2 2025 and $29.9 million for the six months ended June 30, 2025, all recorded in the U.S. via Cardinal Health.
The company recorded a quarterly net loss of $47.9 million and a six-month loss of $118.1 million (basic and diluted loss per share $0.18 and $0.44, respectively). Cash and cash equivalents were $123.8 million and marketable securities $330.5 million at June 30, 2025; management states these balances are sufficient to fund operations for at least 12 months from issuance.
Key balance-sheet items include accounts receivable $26.6 million, inventories $23.9 million (with $2.4 million reserves), and a significant liabilities balance for future royalties and milestones of $250.6 million. The company disclosed FDA approval and U.S. commercial launch of AUCATZYL, MHRA conditional authorization in April 2025, and EU approval in July 2025.
Autolus Therapeutics announced it has released its financial results for the quarter ended June 30, 2025 and provided a corporate update. The company furnished a press release (Exhibit 99.1) and an updated corporate presentation (Exhibit 99.2) that it will use in a conference call; both exhibits are expressly noted as furnished rather than filed.
The 8-K clarifies that the information in the exhibits is not subject to Section 18 liabilities and is not incorporated by reference into other filings unless specifically stated. The form text does not include the underlying financial tables, revenue, expense or cash metrics, so detailed figures and operational commentary must be obtained from the attached Exhibit 99.1 and Exhibit 99.2.
Autolus Therapeutics (Nasdaq:AUTL) filed a Form 8-K reporting the results of its 26 June 2025 Annual General Meeting.
All seven ordinary resolutions passed, including:
- Adoption of the 2024 Annual Report (219.8 M for; 0.1 M against).
- Approval of the directors’ remuneration report (216.0 M for; 4.3 M against).
- Approval of the directors’ remuneration policy (203.4 M for; 16.9 M against).
- Re-appointment of Ernst & Young LLP as auditors (220.3 M for).
- Re-election of directors Dr R. Iannone and Dr R. Rao.
- Adoption of a new Employee Share Purchase Plan authorizing up to 3 million shares.
MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman have disclosed a passive ownership stake in Autolus Therapeutics plc (NASDAQ: AUTL) via Schedule 13G. The group reports beneficial ownership of 15,408,638 American Depositary Shares (ADS), equal to 5.8 % of the company’s 266,141,411 ordinary shares/ADS outstanding as of 7 May 2025. All voting and dispositive authority over the shares is held on a shared basis; none is held solely by any individual entity. MAK Capital Fund is organized in Bermuda, while MAK Capital One L.L.C. and Mr. Kaufman are U.S.-based (Delaware). The filing is made under Rule 13d-1(c), indicating the stake is passive rather than activist; the certification expressly states the securities were not acquired to influence control of the issuer. The event triggering the filing occurred on 17 June 2025, and signatures were executed on 25 June 2025.
The disclosure is material because it crosses the 5 % threshold that requires public reporting, signaling meaningful institutional interest. However, the absence of sole voting power and the passive filing status reduce the likelihood of immediate governance changes. Investors may view the stake as a constructive vote of confidence in Autolus’ long-term prospects without signaling imminent strategic pressure.